Actively Recruiting
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
Led by University of Tennessee · Updated on 2018-09-27
20
Participants Needed
1
Research Sites
80 weeks
Total Duration
On this page
Sponsors
U
University of Tennessee
Lead Sponsor
B
Biocompatibles UK Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.
CONDITIONS
Official Title
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres
- Able to schedule and tolerate additional PET/CT imaging after therapy
- Able to tolerate additional blood draws before, during, and after the radioembolization procedure
You will not qualify if you...
- Not candidates for Y90 radioembolization therapy
- Unable to tolerate additional imaging procedures after therapy
- Unable to tolerate the extra blood draws required for this study
- Schedule does not allow remaining at the hospital for additional PET/CT imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Tennessee Medical Center
Knoxville, Tennessee, United States, 37920
Actively Recruiting
Research Team
D
Dustin Osborne, PhD
CONTACT
S
Shelley Acuff
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here